Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(23 sites)
Australia
Campbelltown Private Hospital, Sydney, New South Wales Mater Hospital Brisbane, Brisbane, Queensland Princess Alexandra Hospital, Brisbane, Queensland Coastal Digestive Health, Maroochydore, Queensland Royal Adelaide Hospital, Adelaide, South Australia Eastern Health Box Hill, Box Hill, Victoria Northern Hospital Epping, Epping, Victoria The Alfred Hospital, Melbourne, Victoria Royal Melbourne Hospital, Parkville, Victoria Canada
University of Calgary, Calgary, Alberta UoA - South Edmonton Gastroenterology Research Clinic, Edmonton, Alberta G.I. Research Institute, Vancouver, British Columbia McGill University Health Center, Montreal, Quebec Netherlands
Erasmus University Medical Center, Holland New Zealand
Aotearoa Clinical Trials, Papatoetoe, Auckland Waikato Hospital, Hamilton Capital Coast and Hutt, Lower Hutt Switzerland
Universitätsspital Zürich, Zurich United Kingdom
Norfolk and Norwich University Hospital, Norwich, Norfolk Cardiff and Vale University Health Board-Wales, Cardiff Royal Liverpool University Hospital, Liverpool St George's University of London, London